Haemonetics Corporation
HAE
$71.65
$1.191.69%
NYSE
| 03/29/2025 | 12/28/2024 | 09/28/2024 | 06/29/2024 | 03/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -3.70% | 3.66% | 8.59% | 7.98% | 12.77% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -3.70% | 3.66% | 8.59% | 7.98% | 12.77% |
| Cost of Revenue | -14.84% | -1.78% | 4.53% | 5.41% | 10.12% |
| Gross Profit | 5.41% | 8.10% | 12.10% | 10.19% | 15.03% |
| SG&A Expenses | 1.36% | -0.34% | -3.09% | -2.26% | 20.64% |
| Depreciation & Amortization | 8.35% | 76.96% | 69.81% | 66.88% | 30.74% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -6.86% | 1.87% | 4.45% | 4.83% | 13.84% |
| Operating Income | 15.10% | 12.07% | 35.35% | 23.08% | 6.80% |
| Income Before Tax | 202.11% | 13.37% | 36.16% | -9.45% | -28.24% |
| Income Tax Expenses | 318.64% | -2.85% | 37.22% | -20.93% | -6.04% |
| Earnings from Continuing Operations | 184.68% | 20.02% | 35.82% | -6.50% | -30.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 184.68% | 20.02% | 35.82% | -6.50% | -30.68% |
| EBIT | 15.10% | 12.07% | 35.35% | 23.08% | 6.80% |
| EBITDA | 14.51% | 15.28% | 32.13% | 24.34% | 11.09% |
| EPS Basic | 193.92% | 21.16% | 35.38% | -7.23% | -31.16% |
| Normalized Basic EPS | 5.16% | 0.87% | 25.83% | 40.39% | -2.39% |
| EPS Diluted | 194.65% | 21.31% | 37.50% | -7.50% | -29.84% |
| Normalized Diluted EPS | 5.83% | 1.52% | 26.64% | 40.90% | -2.10% |
| Average Basic Shares Outstanding | -3.14% | -0.95% | 0.34% | 0.79% | 0.68% |
| Average Diluted Shares Outstanding | -3.76% | -1.57% | -0.30% | 0.44% | 0.37% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |